Sector News

Novo Holdings invests €86m in bioindustrial company 21st.Bio

January 9, 2022
Life sciences

Novo Holdings has made a €86 million investment in 21st.Bio, a Danish bioindustrial scale-up company.

21st.Bio supports bioindustrial companies with matters such as the upscaling of molecular innovation or large-scale production that can meet market demands and advance the green transition globally.

One core focal area for 21st.Bio is producing proteins and peptides that can be utilised for the food, materials and agricultural industries.

21st.Bio’s technology platform originates from selected parts of Novozymes, which provides a co-exclusive license to 21st.Bio within certain boundaries of applications.

Access to selected parts of Novozymes’ R&D platform and the investment by Novo Holdings will enable the company to expand its capabilities even further.

Thomas Schmidt, co-founder and CEO of 21st.Bio, said: “Many brilliant industrial biotech ideas never succeed, because production challenges result in too high price points for the final product. Hence, a vast number of otherwise great innovations do not make it to a scale at which they are truly relevant for the world”.

He continued: “At 21st.Bio, we can help establish the right technology for producing novel molecules and peptides and hence help innovators successfully make the difficult step from innovation to big business and impact for the planet. We have gained access to a selection of Novozymes’ unique technology platform on commercial terms, which means that a success for 21st.Bio is also a success for Novozymes.”

Søren Møller, managing partner of Novo Seeds at Novo Holdings, will join the company’s board of directors.

By Lauren Ford


comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.